Sulanemadlin
InvestigationalAlso known as: ALRN-6924, MP-4897
First-in-class stapled alpha-helical peptide and dual MDM2/MDMX inhibitor that reactivates wild-type p53 tumor suppressor function. Phase 1/2 trials demonstrated 59% disease control rate with notably low hematologic toxicity compared to MDM2-only inhibitors. Novel chemoprotection application being developed for retinoblastoma with Advancium Biosciences partnership.
Research Statistics
Stapled alpha-helical peptide MDM2 inhibitor (ALRN-6924) in Phase 2 oncology trials. Multiple international trial sites. MDM2-p53 interaction disruption mechanism is well-characterized through extensive structural biology; p53 reactivation pathway is established tumor suppressor biology.
Research Dossier
Overview
What is Sulanemadlin and what does the research say?
Mechanism of Action
Sulanemadlin reactivates the p53 tumor suppressor pathway by blocking its negative regulators MDM2 and MDMX.
How It Works (Simplified)
Sulanemadlin acts as a “decoy” that frees p53 to resume its cancer-fighting function:
Binds to MDM2 and MDMX proteins that normally suppress p53, freeing p53 to activate tumor suppressor genes.
Unlike small molecule MDM2 inhibitors, blocks BOTH MDM2 and MDMX simultaneously, preventing resistance escape.
Activated p53 triggers apoptosis in cancer cells through PUMA, BAX, and NOXA gene expression.
In normal cells, p53 activation causes temporary G1 arrest, allowing them to “hide” during chemotherapy exposure.
Scientific Pathways
MDM2/MDMX-p53 Pathway (Tumor Suppression)
Sulanemadlin → Binds MDM2 + MDMX → p53 released from suppression
↓
p53 activates target genes (p21, PUMA, BAX)
↓
Cell cycle arrest + Apoptosis in cancer cellsChemoprotection Pathway (Normal Cell Protection)
Sulanemadlin (pre-chemo) → p53 activation in normal cells → Transient G1 arrest
↓
Normal cells protected during chemo
↓
Effect reverses after clearanceKey Research: Saleh MN et al. (USA, 2019) demonstrated 59% disease control rate with low hematologic toxicity in Phase 1/2 trial. PMID:31852831
Important Limitations
- Requires TP53 wild-type status; ineffective in TP53-mutant tumors
- Currently investigational with no regulatory approvals
- Administered IV only; oral formulation not available
- Long-term safety data limited to Phase 1/2 trial durations
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
IV infusion on days 1, 4, 8, 11 of 21-day cycle. Rapid p53 pathway activation confirmed by serum MIC-1/GDF-15 elevation within hours of dosing. Dose-dependent pharmacodynamic response observed.
Disease stabilization may become apparent. Tumor marker changes and imaging assessment typically at cycle 2. Chemoprotection effect (reduced neutropenia) evident by day 14 in combination protocols.
Response assessment per RECIST criteria. Lymphoma responses observed as early as cycle 2-3. Continued tolerability with low rates of dose-limiting toxicity. Cumulative fatigue possible.
Durable disease control in responding patients. Some responses maintained beyond 6 months. Long-term treatment feasible due to favorable hematologic safety profile compared to MDM2-only inhibitors.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Sulanemadlin product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Sulanemadlin with other peptides. Based on published research and mechanistic considerations.
Idasanutlin
CautionBoth target MDM2-p53 pathway. Combining MDM2 inhibitors could cause excessive p53 activation and increased toxicity. Not recommended for co-administration.
Navtemadlin
CautionOverlapping MDM2 inhibition mechanism. Concurrent use may increase risk of hematologic toxicity. Clinical combination not studied.
Milademetan
CautionSimilar MDM2-targeting mechanism. Potential for additive toxicity if combined. No clinical data on co-administration.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Sulanemadlin
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.